SEC Info - Institutional Equity Holdings Inc/NV

SEC Info℠

Home

Help

Please Sign In

Institutional Equity Holdings Inc/NV – ‘PRE 14A’ for 5/26/97

As of: Friday, 4/18/97 · For: 5/26/97 · Accession #: 950134-97-3038 · File #: 0-27720

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 4/18/97  Inst’l Equity Holdings Inc/NV     PRE 14A     5/26/97    1:54K                                    RR Donnelley

Preliminary Proxy Solicitation Material — Schedule 14A
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: PRE 14A     Preliminary Proxy Materials                           16     89K

Document Table of Contents

Page	(sequential)	\|	(alphabetic)	Top
			Alternative Formats (Word, et al.) Employment Agreements Proposal I -- Election of Directors
1	1st Page - Filing Submission
5	Proposal I -- Election of Directors
11	Employment Agreements

PRE 14A 1st Page of 16 TOC ↑Top Previous Next ↓Bottom Just 1st

SCHEDULE 14A
(RULE 14A-101)

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934

Filed by the Registrant [X]
Filed by a Party other than the Registrant [ ]
Check the appropriate box:
[X] Preliminary Proxy Statement [X] Confidential, for Use of the
Commission Only (as permitted by
Rule 14a-6(e)(2))
[ ] Definitive Proxy Statement
[ ] Definitive Additional Materials
[ ] Soliciting Material Pursuant to sec. 240.14a-11(c) or sec. 240.14a-12

EUROMED, INC.
--------------------------------------------------------------------------------
(Name of Registrant as Specified in its Charter)

--------------------------------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):
[X] No fee required.
[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(l) and
0-11.

(1) Title of each class of securities to which transaction applies: N/A

--------------------------------------------------------------------------------
(2) Aggregate number of securities to which transaction applies: N/A

--------------------------------------------------------------------------------
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee
is calculated and state how it was determined):
N/A
--------------------------------------------------------------------------------
(4) Proposed maximum aggregate value of transaction:

--------------------------------------------------------------------------------
(5) Total fee paid:

--------------------------------------------------------------------------------

[ ] Fee paid previously with preliminary materials.

[ ] Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number, or
the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

--------------------------------------------------------------------------------
(2) Form, Schedule or Registration Statement No.:

--------------------------------------------------------------------------------
(3) Filing Party:

--------------------------------------------------------------------------------
(4) Date Filed:

--------------------------------------------------------------------------------

PRE 14A 2nd Page of 16 TOC 1st Previous Next ↓Bottom Just 2nd

EUROMED, INC.
WILHELMINAKANAAL NOORD 6
NL 4902 VR OOSTERHOUT
THE NETHERLANDS

April 30, 1997

Dear Stockholder:

You are cordially invited to attend the Annual Meeting of Stockholders (the
"Meeting") of EuroMed, Inc., a Nevada corporation ("EuroMed"), to be held at
10:00 a.m., local time, on May 26, 1997, at Grosvenor House London, 86 Park
Lane, Park Lane London WIA 3AA, England. The attached Notice of Annual Meeting
and Proxy Statement describe the formal business to be transacted at the
Meeting. We have enclosed a copy of EuroMed's Annual Report for the fiscal year
ended December 31, 1996.

Directors and officers of EuroMed are expected to be present to help host
the Meeting and to respond to any questions that our stockholders may have. I
hope that you will be able to attend.

EuroMed's Board of Directors believes that a favorable vote on each of the
matters to be considered at the Meeting is in the best interest of EuroMed and
its stockholders and recommends a vote "FOR" each such matter. Accordingly, we
urge you to review the attached material carefully and to return the enclosed
Proxy promptly. Whether or not you plan to attend the Meeting, you may vote in
person if you wish, even though you have previously returned your proxy. It is
important that your shares be represented and voted at the Meeting.

On behalf of your Board of Directors, thank you for your support.

Sincerely,

Robert W. L. Veldman,
Chief Executive Officer and President

PRE 14A 3rd Page of 16 TOC 1st Previous Next ↓Bottom Just 3rd

CONFIDENTIAL -- FOR USE OF THE COMMISSION ONLY
(AS PERMITTED BY RULE 14(a)-6(e)(2))

EUROMED, INC.
Wilhelminakanaal Noord 6
NL 4902 VR Oosterhout
The Netherlands

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD MAY 26, 1997

NOTICE IS HEREBY GIVEN that the Annual Meeting of Stockholders (the
"Meeting") of EuroMed, Inc. (the "Company") will be held at 10:00 a.m., local
time, on May 26, 1997, at the Grosvenor House London, 86 Park Lane, Park Lane
London WIA 3AA, England, for the following purposes:

(1) To elect five members of the Board of Directors (constituting the
entire Board of Directors) to serve until the next Annual Meeting of
Stockholders and until their respective successors shall be elected and
qualified.

(2) To approve the sale of Pluripharm International B.V., a subsidiary
of the Company.

(3) To ratify the selection of Killman, Murrell & Company, P.C. as
independent public accountants for the Company for the fiscal year ending
December 31, 1997.

(4) Such other business as may properly come before the Meeting or any
adjournments thereof.

The close of business on April 18, 1997 has been fixed as the record date
for determining stockholders entitled to notice of and to vote at the Meeting or
any adjournments thereof. For a period of at least 10 days prior to the Meeting,
a complete list of stockholders entitled to vote at the Meeting will be open for
examination by any stockholder during ordinary business hours at the offices of
EuroMed, Inc. at Wilhelminakanaal Noord 6, NL 4902 VR Oosterhout, The
Netherlands.

Information concerning the matters to be acted upon at the Meeting is set
forth in the accompanying Proxy Statement.

YOUR VOTE IS IMPORTANT. WHETHER OR NOT YOU EXPECT TO ATTEND THE MEETING, PLEASE
COMPLETE, DATE AND SIGN THE ENCLOSED PROXY AND MAIL IT PROMPTLY TO ASSURE THAT
YOUR SHARES ARE REPRESENTED AT THE MEETING. A RETURN ENVELOPE (WHICH IS POSTAGE
PREPAID IF MAILED IN THE UNITED STATES) IS PROVIDED. EVEN IF YOU HAVE GIVEN YOUR
PROXY, YOU MAY STILL VOTE IN PERSON IF YOU ATTEND THE MEETING. PLEASE NOTE,
HOWEVER, THAT IF YOUR SHARES ARE HELD OF RECORD BY A BROKER, BANK OR OTHER
NOMINEE AND YOU WISH TO VOTE AT THE MEETING, YOU MUST OBTAIN FROM THE RECORD
HOLDER A PROXY ISSUED IN YOUR NAME.

By Order of the Board of Directors,

Richard F. Dahlson
Secretary
Dallas, Texas
April 30, 1997

PRE 14A 4th Page of 16 TOC 1st Previous Next ↓Bottom Just 4th

EUROMED, INC.
WILHELMINAKANAAL NOORD 6
NL 4902 VR OOSTERHOUT
THE NETHERLANDS

PROXY STATEMENT
FOR

ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD MAY 26, 1997

This Proxy Statement is being first mailed on or about May 1, 1997 to
stockholders of EuroMed, Inc., a Nevada corporation (the "Company"), by the
Board of Directors to solicit proxies (the "Proxies") for use at the Annual
Meeting of Stockholders (the "Meeting") to be held at 10:00 a.m., local time, on
May 26, 1997, at the Grosvenor House London, 86 Park Lane, Park Lane London WIA
3AA, England, or at such other time and place to which the Meeting may be
adjourned (the "Meeting Date").

The purpose of the Meeting is to consider and act upon (i) the election of
five directors (constituting the entire Board of Directors) to serve until the
next Annual Meeting of Stockholders and until their respective successors shall
be elected and qualified, (ii) the approval of the sale of Pluripharm
International B.V., a subsidiary of the Company ("Pluripharm"), (iii) the
ratification of the selection of Killman, Murrell & Company, P.C. as independent
public accountants for the Company for the fiscal year ending December 31, 1997,
and (iv) such other matters as may properly come before the Meeting or any
adjournments thereof.

All shares represented by valid Proxies, unless the stockholder otherwise
specifies, will be voted (i) FOR the election of the persons named herein under
"PROPOSAL I -- ELECTION OF DIRECTORS" as nominees for election as directors of
the Company for the term described therein, (ii) FOR the sale of Pluripharm,
(iii) FOR the ratification of the selection of Killman, Murrell & Company, P.C.
as independent public accountants for the Company for the fiscal year ending
December 31, 1997 and (iv) at the discretion of the Proxy holders with regard to
any other matter that may properly come before the Meeting or any adjournments
thereof.

Where a stockholder has appropriately specified how a Proxy is to be voted,
it will be voted accordingly. The Proxy may be revoked at any time by providing
written notice of such revocation to American Stock Transfer & Trust Company, 40
Wall Street, 46th Floor, New York, New York 10005, Attention: Donna Ansbro. If
notice of revocation is not received by the Meeting Date, a stockholder may
nevertheless revoke a Proxy if the stockholder attends the Meeting and desires
to vote in person.

RECORD DATE AND VOTING SECURITIES

The record date for determining the stockholders entitled to vote at the
Meeting is the close of business on April 18, 1997 (the "Record Date"), at which
time the Company had issued and outstanding 3,118,000 shares of common stock,
par value $.01 per share (the "Common Stock"). The Common Stock is the only
outstanding voting securities of the Company.

QUORUM

The presence at the Meeting, in person or by proxy, of the holders of a
majority of the issued and outstanding shares of Common Stock is necessary to
constitute a quorum to transact all business to come before the Meeting.

PRE 14A 5th Page of 16 TOC 1st Previous Next ↓Bottom Just 5th

PROPOSAL I -- ELECTION OF DIRECTORS

Five directors are to be elected, each director to hold office for a term
of one year or until his successor shall have been elected and qualified. The
Board of Directors has nominated the five persons named below to serve as
directors. Three of the nominees, Messrs. Hinnen, Shelmire and Shuey, are
currently members of the Board of Directors. In order to be elected a director,
a nominee must receive a plurality of the votes of the shares of Common Stock
present in person or represented by Proxy at the Meeting. Votes that are
withheld and broker non-votes will be counted toward a quorum, but will not be
counted in the election of directors.

THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR THE ELECTION OF THE NOMINEES
NAMED HEREIN (ITEM NO. 1 ON THE ENCLOSED PROXY CARD).

Each of the nominees has indicated his willingness to serve as a member of
the Board of Directors if elected; however, in case any nominee shall become
unavailable for election to the Board of Directors for any reason not presently
known or contemplated, the Proxy holders have discretionary authority to vote
the Proxy for a substitute nominee or nominees. The following sets forth
information as of April 16, 1997 as to the nominees for election at the Meeting,
including their ages, present principal occupations, other business experience
during the last five years, membership on committees of the Board of Directors
and directorships in other publicly-held companies.

[Download Table]

NAME AGE POSITION
---- --- --------

A. Francois Hinnen....................... 54 Chairman of the Board
Robert W. L. Veldman..................... 48 Chief Executive Officer and President
David Anderson........................... 41 Chief Financial Officer
Jesse Shelmire, IV....................... 39 Director
Robert A. Shuey, III(1).................. 42 Director

---------------

(1) Member of the Audit Committee and the Compensation Committee.

A. Francois Hinnen, MSc has served as Chairman of the Board of the Company
since November 18, 1995. Mr. Hinnen served as Chief Executive Officer of the
Company from November 18, 1995 until October 31, 1996, and as President of the
Company from November 18, 1995 until February 28, 1997, and has served, through
a controlled company, as the Managing Director of Galenica B.V. ("Galenica") and
Confedera B.V. ("Confedera") since January 1991. Mr. Hinnen has also served the
Company as the chief pharmacist for Galenica and Confedera, which are wholly
owned Subsidiaries of the Company organized under the laws of The Netherlands.
Mr. Hinnen has 28 years experience as a certified pharmacist and 24 years
business experience as an entrepreneur in the pharmaceutical industry. Mr.
Hinnen graduated first of year in 1967 with a Masters in Mathematics and Natural
Sciences, and in 1968 with a degree in Microbiology and Pharmacy from the
University of Utrecht, The Netherlands. Mr. Hinnen was a member of the staff of
the University of Nijmegen, The Netherlands, from 1969-1970.

Robert W. L. Veldman, MSc has served as Chief Executive Officer of the
Company since February 1997. Mr. Veldman has twenty-three years related health
care management experience. Before joining EuroMed, Mr. Veldman worked as
director of business development at Merck, Sharp & Dohme B.V. in Haarlem from
1995 to 1997. Prior to that he worked as Pharmaceutical Director and Managing
Director Hospital Division, Brocacef BV -- Maarssen from 1988 to 1995, as
Director of European Operations, Centocor Europe BV -- Leiden from 1987 to 1988
and served as managing director and chief operating officer of Centrafarm Group
NV -- Etten Leur from 1978 to 1987 and as an industrial pharmacist, Organon
International BV -- Oss from 1975 to 1978.

David Anderson has served as the Company's Chief Financial Officer since
February 1997. Mr. Anderson brings fifteen years of healthcare experience in the
United States, including experience in the home infusion drug market as well as
the free standing and hospital based home nursing and equipment service
businesses. Mr. Anderson served as western division vice president of Nurse
Finders, Inc., a home health and medical staffing company, from 1995 to 1997 and
served as director and senior vice president of operations for OptionCare, Inc.,
a Home Infusion Therapy Company, from 1993 to 1995. Prior to that, he founded
and was

PRE 14A 6th Page of 16 TOC 1st Previous Next ↓Bottom Just 6th

an equity director and chief development officer for Earthstone, a Division of
EPIC Health Care Group, from 1990 to 1993, served as executive vice president of
ABC Home Health, a privately held home health care company, from 1987 to 1990
and served as associate and district director for T-2 Medical Management, a Home
Infusion Therapy provider company.

Jesse Shelmire, IV has served as a director of the Company since November
27, 1996. Mr. Shelmire has 15 years of experience in the investment banking and
stock underwriting business. Upon graduating from the Warton School of Business
he worked from 1981 to 1989, for Smith Barney, Inc. in their Dallas, Texas
office. From 1989 to 1993, he served as the Portfolio Manager for Stonegates
Securities, Inc. of Dallas, Texas where he managed $250 million of assets in
equity and fixed income accounts and served at Dillon-Gage Securities Corp. as
Director of Corporate Finance from 1993 to 1995 and served as Director of
Corporate Finance for LaJolla Securities Corporation from 1994 to 1995. Mr.
Shelmire currently serves as Managing Director of Investment Banking for First
London Securities Corporation in Dallas, Texas.

Robert A. Shuey, III has served as a director of the Company since June
1996. Mr. Shuey is employed by National Securities Corporation of Dallas, Texas
as the Director of Corporate Finance. Prior to that, Mr. Shuey was with LaJolla
Securities from 1994 to 1995 in the position of Director of Corporate Finance.
Mr. Shuey was employed as Director of Corporate Finance by Dillon-Gage
Securities Corp., an investment banking firm, from 1994 to 1995, and prior to
that held the position of Senior Vice President, Corporate Finance, of Dickinson
& Company, a brokerage firm. Mr. Shuey was Vice President of Rauscher Pierce
Refnes, Inc. from June 1984 to September 1987. From May 1980 until June 1984, he
was director of the corporate finance department and a Vice President of
Institutional Equity Corporation. Prior to that time, Mr. Shuey was an associate
in the corporate finance department of Salomon Brothers, Inc.

MEETINGS AND COMMITTEES OF THE BOARD OF DIRECTORS

The business of the Company is managed under the direction of the Board of
Directors. The Board of Directors meets on a regularly scheduled basis to review
significant developments affecting the Company and to act on matters requiring
approval of the Board of Directors. It also holds special meetings when an
important matter requires action by the Board of Directors between scheduled
meetings. The Board of Directors met seven times and acted by unanimous written
consent two times during 1996. During 1996, each member of the Board of
Directors participated in at least 75% of all Board of Directors meetings during
the period for which he was a director.

The Board of Directors has two standing committees: the Audit Committee and
the Compensation Committee. The functions of these committees, their current
members, and the number of meetings held during fiscal 1996 are described below.

Audit Committee. The Audit Committee makes recommendations to the Board of
Directors regarding the appointment of independent auditors, reviews the plan
and scope of any audit to the Company's financial statements and reviews the
Company's significant accounting policies and related matters. Mr. Shuey
currently is the sole member of the Audit Committee. The Audit Committee did not
meet in 1996.

Compensation Committee. The Compensation Committee makes recommendations to
the Board of Directors regarding the compensation of executive officers and the
administration of the Company's 1995 Long-Term Incentive Plan. Mr. Shuey
currently is the sole member of the Compensation Committee. The Compensation
Committee did not meet in 1996.

Nominating Committee. The Company does not have a nominating committee. The
functions customarily performed by a nominating committee are performed by the
Board of Directors as a whole.

PRE 14A 7th Page of 16 TOC 1st Previous Next ↓Bottom Just 7th

PROPOSAL II -- SALE OF PLURIPHARM

On March 26, 1997, the Board of Directors approved a five-point
restructuring plan. This restructuring plan consisted of the following: (i) a
settlement of all claims between the Company and A. Doets and N.T.P. Roozekrans,
the former owners of Pluripharm International B.V. ("Pluripharm"), in
consideration for which Messrs. Doets and Roozekrans would assign and deliver to
the Company 850,000 shares of Common Stock (the "Settlement"); (ii) the sale of
all of the capital stock of Pluripharm (the "Sale"); (iii) the give-back by Mr.
Hinnen and his affiliates of 850,000 shares of Common Stock (the "Hinnen
Give-Back"); (iv) the plan to repurchase in the open-market from time to time up
to 300,000 shares of Common Stock (the "Repurchase Plan"); and (v) the
undertaking of a new strategy of acquiring healthcare related companies or
assets outside of The Netherlands, including possible purchases of health care
companies or assets in the United States (the "New Strategy").

Pursuant to a Settlement Agreement, dated as of April 18, 1997 (the
"Settlement Agreement"), by and among the Company, Mr. Doets, Mr. Roozekrans and
certain other parties, the Settlement was agreed to, and will be closed on June
2, 1997. Accordingly, on April 18, 1997, 850,000 shares of Common Stock have
been returned to the Company and are no longer issued and outstanding.

Pursuant to a Share Purchase Agreement, dated as of April 3, 1997 (the
"Share Purchase Agreement"), by and among the Company, EuroMed Europe B.V.
("EuroMed Europe") and Mutarestes B.V. ("Mutarestes") (collectively, the
"EuroMed Group") and Houdstermaatschappij Singultus B.V. I.O. ("Purchaser"), the
EuroMed Group has agreed to sell to Purchaser all of the capital stock of
Pluripharm, at a purchase price of approximately $2,800,000, consisting of a
pre-closing dividend from Pluripharm to Mutarestes of approximately $400,000,
and the payment at the closing of the Sale by Purchaser to the EuroMed Group of
approximately $2,400,000 cash (the "Purchase Price"). The closing of the Sale to
occur on June 2, 1997, is subject to the following conditions: (i) receipt by
the Company of a statement (the "Fairness Opinion") of the firm Paardekooper &
Hoffman or a financial advisory firm of the same reputation, in which the value
of Pluripharm is determined and in which it is declared that the Purchase Price
is considered to be a fair consideration and a reasonably equivalent value to
the EuroMed Group and its stockholders; and (ii) approval of the sale by the
stockholders of EuroMed (the "Stockholder Approval"). The Company has received
the Fairness Opinion, a copy of which is attached hereto as Appendix A, and
described below, and by this Proxy Statement is seeking to obtain Stockholder
Approval.

B.V. Wisteria ("Wisteria"), the holder of 1,923,130 shares of Common Stock
(61.67% of the issued and outstanding shares of Common Stock) has entered into a
Compensation Agreement with Purchaser (the "Compensation Agreement"), which
provides, among other things, that Wisteria will take all actions within its
powers as the majority stockholder of the Company to cause the Stockholder
Approval to be received, and in the event Stockholder Approval is not received
(due to an event within the power of Wisteria) or the Fairness Opinion is not
furnished, in each case by or before May 27, 1997, and, as a result thereof, the
Share Purchase Agreement is rescinded by the Company, Wisteria shall pay
Purchaser 500,000 Dutch Guilders. Mr. Hinnen, the controlling shareholder of
Wisteria, has indicated that he will vote all shares of Common Stock owned by
Wisteria in favor of the Sale, thereby assuring the approval thereof.

EuroMed acquired Pluripharm in July 1996 from personal holding companies
owned by Messrs. Doets and Roozekrans, for a purchase price consisting of (i) 10
million Dutch guilders and (ii) 850,000 shares of Common Stock. The Company is
taking this step primarily as a result of the changing pharmaceutical wholesale
market in The Netherlands, which has resulted in significantly lowered prices
and decreased margins, and the Company's inability to consolidate the Pluripharm
operations into the Company's operations in The Netherlands. In the Company's
1996 financial statements, Pluripharm was considered as discontinued operations.
Further, there are no U.S. tax consequences or benefits from the loss on the
Pluripharm transaction until the Company divests of its European subsidiaries.
The Sale and the related Settlement will result in the Company recognizing a
loss of approximately $3,200,000. Messrs. Doets and Roozekrans negotiated the
Share Purchase Agreement on behalf of the Purchaser.

PRE 14A 8th Page of 16 TOC 1st Previous Next ↓Bottom Just 8th

Simultaneously with the closing of the Share Purchase Agreement, the Hinnen
Give-Back shall occur, after which time, and from time to time, the Company may
purchase up to 500,000 shares of Common Stock in the open market pursuant to the
Repurchase Plan. In addition, management is currently pursuing the New Strategy
and is actively seeking and reviewing possible acquisition candidates, although
no agreements have been entered into at this time. Management believes that the
cash to be received in the Sale will allow the Company to pursue the New
Strategy, with the intention of bringing greater value to the stockholders of
the Company.

The following is a table of certain selected financial data of EuroMed for
the last five years of operations:

[Enlarge/Download Table]

1992 1993 1994 1995 1996
-------- --------- --------- --------- ---------
(IN THOUSANDS OF US DOLLARS, EXCEPT FOR PER SHARE DATA)

Income Statement Data
Sales............................... $6,780 $12,470 $20,271 $32,978 $35,471
Gross Profit........................ 659 1,362 2,027 3,356 3,045
Operating Profit (Loss)............. 179 590 915 1,256 (297)
Net Income (Loss) from Continuing
Operations....................... 118 444 687 836 (481)
Earnings (Loss) Per Share
Continued Operations............. .06 .22 .34 .42 $ (0.15)
Discontinued Operations.......... (1.00)
-------
Total Earnings (Loss) Per Share
Based on the weighted
average number of shares
outstanding of
3,190,000................. $ (1.15)
-------

The following is a table of Selected Financial Data comparing the
Pluripharm Divisions last 4 years of operating.

[Enlarge/Download Table]

IN THOUSANDS OF
IN THOUSANDS OF DFL U.S. DOLLARS
------------------------------------- -----------------
1993 1994 1995 1996 1995 1996
------- ------- ------- ------- ------- -------

INCOME STATEMENT DATA
Sales.............................. $39,125 $41,601 $50,664 $59,225 $31,539 $35,125
Gross Profit....................... 2,529 7,607 4,140 4,774 2,577 2,831
Operating Profit................... 2,962 2,815 3,469 3,269 2,160 1,939
Net Income......................... 1,899 1,811 2,256 2,126 1,405 1,260

BALANCE SHEET DATA AT YEAR END
Inventory.......................... -- 1,841 2,144 2,543 1,338 1,458
Total Current Assets............... -- 9,829 14,104 11,884 8,801 6,812
Current Liabilities................ -- 9,724 13,987 9,609 8,728 5,508
Long-Term Debt..................... -- -- -- -- -- --
Stockholders' Equity............... -- 128 296 2,422 184 1,388

The fairness opinion sought by EuroMed with regard to the sale has been
provided by Paardekooper and Hoffman of Amsterdam, The Netherlands, which is one
of the top 10 largest accounting firm in The Netherlands. This firm was chosen
by the parties in an arms-length transaction. EuroMed's management along with
the Purchaser believes that this firm is qualified to research and render an
opinion as to the fairness of the transaction. Paardekooper & Hoffman are the
Dutch affiliate of Killman and Murrel & Company, P.C., the Company's independent
public accountants for the fiscal year ending 1996. Further, Paardekooper &
Hoffman was reimbursed for their work on EuroMed's 1996 year end audit and
continue to serve the Company as an affiliate of the Company's independent
auditor.

PRE 14A 9th Page of 16 TOC 1st Previous Next ↓Bottom Just 9th

[Summary of fairness opinion to come.]

The fairness opinion issued is an opinion on the terms and price agreed
upon by EuroMed and the Purchaser. Neither the terms nor the price have been set
or negotiated by Paardekooper & Hoffman and in management's opinion the fairness
opinion they have rendered is independent and substantiated by the facts as
discovered.

The affirmative vote of the holders of [a majority of the outstanding
shares of Common Stock is required for approval of the Sale.] Abstentions and
Broker Non-Votes will have the effect of votes against the Sale.

THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR THE SALE (ITEM NO. 2 ON THE
ENCLOSED PROXY CARD).

PROPOSAL III -- INDEPENDENT PUBLIC ACCOUNTANTS

On November 19, 1996, KPMG Accountants N.V. ("KPMG") resigned as EuroMed's
independent public accountant. No report of KPMG for EuroMed contained an
adverse opinion or a disclaimer of opinion, or was qualified or modified as to
uncertainty, audit scope or accounting principles. There have been no
disagreements between KPMG and EuroMed as described in Item 304(a)(1)(iv) of
Regulation S-K or events of the kind set forth in Item 304(a)(1)(v) of
Regulation S-K.

EuroMed provided KPMG with the above disclosures prior to filing a Current
Report Form 8-K with the Securities and Exchange Commission. KPMG responded to
the above disclosures by stating that they resigned as principal accountants for
EuroMed because they believed that the control structure of EuroMed was not
adequate to develop reliable financial statements. KPMG did not disclose to
EuroMed specific concerns or problems.

On February 20, 1997, EuroMed engaged Killman, Murrell and Company, P.C.
("Killman") as its independent public accountant. Prior to engaging Killman,
EuroMed discussed with Killman the reason given by KPMG for its resignation.
Killman has told EuroMed that it believes EuroMed has resolved the problems that
led to KPMG's resignation. EuroMed provided Killman with the above disclosures
prior to filing a Current Report on Form 8-K with the Commission and Killman did
not file any response to such disclosures.

The Board of Directors has selected Killman as independent auditors to
examine the Company's accounts for the current fiscal year. It is expected that
representatives of Killman will be present at the Meeting, will be available to
respond to appropriate questions of stockholders and will have an opportunity to
make a statement if they desire.

Ratification of Killman as independent public accountants requires the vote
of a majority of the votes represented and entitled to vote at the Meeting.
Abstentions on this proposal may be specified and will have the same effect as a
vote against such proposal. Broker non-votes will not be counted as having been
voted with respect to this proposal.

THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR THE RATIFICATION OF THE
SELECTION OF KILLMAN, MURRELL & COMPANY, P.C. AS THE COMPANY'S INDEPENDENT
PUBLIC ACCOUNTANTS FOR THE FISCAL YEAR ENDING DECEMBER 31, 1997.

EXECUTIVE OFFICERS

The executive officers of the Company are Messrs. Hinnen, Veldman and
Anderson. Information regarding such persons is provided above under Proposal I.

PRE 14A 10th Page of 16 TOC 1st Previous Next ↓Bottom Just 10th

PRINCIPAL STOCKHOLDERS AND MANAGEMENT OWNERSHIP

The following table sets forth information with respect to beneficial
ownership of Common Stock as of April 16, 1997 by (i) all persons known to the
Company to be the beneficial owner of 5% or more of the Common Stock, (ii) each
director of the Company, (iii) the chief executive officer and each of the
Company's four other most highly compensated executive officers whose total
annual compensation for 1996 based on salary and bonus earned during 1996
exceeded $100,000 (the "Named Executive Officers"), and (iv) all the Company
directors and executive officers as a group. This table does not include shares
of Common Stock that may be purchased pursuant to options not exercisable within
60 days of April 16, 1997. All persons listed have sole voting and investment
power with respect to their shares unless otherwise indicated.

[Enlarge/Download Table]

AMOUNT AND NATURE PERCENT
OF BENEFICIAL OF
NAME OF BENEFICIAL OWNER OWNERSHIP CLASS
------------------------ ----------------- --------

A. Francois Hinnen, MSc(1)............................... 1,923,130 61.67%
Robert W. L. Veldman, MSc................................ -- --
David Anderson........................................... -- --
Jesse Shelmire, IV....................................... 14,000(2) *
Robert A. Shuey, III..................................... 20,000(2) *
Gregory A. Gaylor........................................ 125,000 4.00%
Louis van den Reek....................................... -- --
All directors and executive officers as a group (7
persons)............................................... 2,054,630 65.87%

---------------

* Less than 1%

(1) The 1,923,130 shares beneficially owned by Mr. Hinnen are owned directly
through B.V. Wisteria, a Netherlands limited liability company, which
company is owned by Pantapharma B.V., which is owned by Mr. Hinnen.
Additionally, Mr. Hinnen holds the voting power over 22,000 shares through
an irrevocable proxy which expires on June 30, 1997. Mr. Hinnen's address is
Beekhuizenseweg 87, 6881 A.G. Velp, The Netherlands.

(2) Consists of warrants to purchase Common Stock, which warrants were issued in
connection with the Company's initial public offering (the "Representatives
Warrants"). In addition, first London Securities Corporation was issued
20,000 Representative Warrants, which Mr. Shelmire disclaims beneficial
ownership.

(3) Consists of 20,000 Representative Warrants. In addition, National Securities
Corporation was issued 6,667 Representatives Warrants, which Mr. Shuey
disclaims beneficial ownership.

LITIGATION

EuroMed, Inc. has filed two separate lawsuits against one of its directors,
Gregory Alan Gaylor. The first, Case No. A366523, was filed against Mr. Gaylor
and Mr. Robert Jansonius, a former director of EuroMed, in the State District
Court of Clark County, Nevada on November 15, 1996. In the suit, the Company
alleges that Mr. Gaylor acted improperly by diverting Company funds to improper
uses, representing himself as having managerial authority over Company affairs,
and making untrue statements regarding Company business. The Company seeks
temporary and permanent injunctive relief prohibiting Mr. Gaylor from taking
certain actions, and the Court has granted a temporary restraining order and has
signed an order granting a preliminary injunction in the Company's favor. The
Company is in the process of negotiating a settlement agreement with Mr.
Jansonius.

The second lawsuit against Mr. Gaylor was initiated on February 18, 1997 in
Dallas, Texas in the United States District Court for the Northern District of
Texas, and bears Civil Action No. 3-97CV0322-H. The lawsuit alleges that Mr.
Gaylor violated Section 13(d) of the Securities Exchange Act of 1934, as
amended, by failing to make necessary federal securities law filings upon his
acquisition of more than a 5% beneficial interest in the Company's Common Stock.
In addition, the Company has requested injunctive relief and damages resulting
from Mr. Gaylor's alleged disparagement of the Company and Mr. Gaylor's alleged

PRE 14A 11th Page of 16 TOC 1st Previous Next ↓Bottom Just 11th

interference with the Company's operations arising from his communications with
the Company's investors, customers, stockholders and accountants.

EXECUTIVE COMPENSATION

The following table sets forth certain information regarding compensation
paid during the Company's last completed fiscal year to the Company's Chief
Executive Officer and each of the Company's executive officers (other than the
Chief Executive Officer) whose total annual salary and bonuses earned during the
fiscal year ended December 31, 1996, exceeded $100,000:

MANAGEMENT COMPENSATION AND TRANSACTIONS

SUMMARY COMPENSATION TABLE

[Enlarge/Download Table]

LONG-TERM
ANNUAL COMPENSATION COMPENSATION AWARDS
--------------------------------------------- ----------------------------
SECURITIES
UNDERLYING
OTHER OPTIONS/ ALL OTHER
NAME/TITLE YEAR SALARY($) BONUS($) COMPENSATION($) SARS(#) COMPENSATION($)
---------- ---- --------- -------- --------------- ---------- ---------------

A. Francois Hinnen(1) 1996 $125,000 -- -- -- --
1995 $125,000 -- -- -- --

---------------

(1) Mr. Hinnen contracts his services to Confedera and Galenica through
Pantapharma B.V. See "Employment Agreements."

COMPENSATION OF DIRECTORS

The Company pays $3,500 per quarter to its directors who are not employees
or affiliates of the Company ("Independent Directors"). In addition, Independent
Directors may receive options to purchase Common Stock under the Company's 1995
Long-Term Incentive Plan.

EMPLOYMENT AGREEMENTS

Mr. Hinnen provides his services to Confedera B.V., a wholly-owned
subsidiary of the Company ("Confedera"), through a management agreement ("Hinnen
I Agreement") between Confedera, and Pantapharma B.V., a Netherlands private
limited liability company ("Pantapharma"). Pursuant to the Hinnen I Agreement,
Pantapharma has agreed to fulfill the duties assigned to a director of Confedera
for a period commencing on January 1, 1995 through December 31, 1999, for which
Confedera has agreed to pay Pantapharma a management fee of approximately
$62,000, excluding sales tax, subject to review annually (with the understanding
that the management fee shall be annually increased by a percentage equal to the
price index figure for family consumption as determined by the Central Bureau of
Statistics of The Netherlands). In addition, Confedera has agreed to reimburse
Pantapharma for all business expenses incurred by Pantapharma for acting, in
such capacity, including, an automobile allowance of approximately $.37 per
kilometer. The Hinnen I Agreement is terminable by either party on at least one
year prior written notice. In the event Confedera terminates the Hinnen I
Agreement prior to the expiration of the term without cause (with cause being
defined as: (i) failure by Pantapharma to fulfill its duties and obligations
under the Hinnen I Agreement; (ii) Pantapharma has been adjudicated bankrupt or
has been granted suspension of payment; or (iii) Pantapharma for a continuous
period of thirteen weeks or more has not placed any staff at the disposal of
Confedera for the execution of the Hinnen I Agreement), Pantapharma shall be
entitled to continue to receive the management fee for the remainder of the
term. In the event Pantapharma is unable to fulfill its duties and obligations
under the Hinnen I Agreement for any reason, Pantapharma shall be entitled to
receive the management fee for one-year thereafter.

Mr. Hinnen provides his services to Galenica B.V., a wholly-owned
subsidiary of the Company ("Galenica"), through a management agreement ("Hinnen
II Agreement") between Galenica and Pantapharma. Pursuant to the Hinnen II
Agreement, Pantapharma has agreed to fulfill the duties assigned to

PRE 14A 12th Page of 16 TOC 1st Previous Next ↓Bottom Just 12th

a director of Galenica for a period commencing on January 1, 1995 through
December 31, 1999, for which Galenica has agreed to pay Pantapharma a management
fee of approximately $62,000, excluding sales tax, subject to review annually
(with the understanding that the management fee shall be annually increased by a
percentage equal to the price index figure for family consumption as determined
by the Central Bureau of Statistics of The Netherlands). In addition, Galenica
has agreed to reimburse Pantapharma for all business expenses incurred by
Pantapharma for acting in such capacity, including an automobile allowance of
approximately $.37 per kilometer. The Hinnen II Agreement is terminable by
either party on at least one-year prior written notice. In the event Galenica
terminates the Hinnen II Agreement prior to the expiration of the term without
cause (with cause being defined as: (i) failure by Pantapharma to fulfill its
duties and obligations under the Hinnen II Agreement; (ii) Pantapharma has been
adjudicated bankrupt or has been granted suspension of payment; or (iii)
Pantapharma for a continuous period of thirteen weeks or more has not placed any
staff at the disposal of Galenica for the execution of the Hinnen II Agreement),
Pantapharma shall be entitled to continue to receive the management fee for the
remainder of the term. In the event Pantapharma is unable to fulfill its duties
and obligations under the Hinnen II Agreement for any reason, Pantapharma shall
be entitled to receive the management fee for one-year thereafter.

David Anderson provides his services to EuroMed through a management
agreement between EuroMed, Inc. and the Anderson Group, a sole proprietorship.
This contractual relationship states that Mr. Anderson will be reimbursed for
his company related expenses and a $10,000 per month management fee. The term of
this contract is for six months beginning February 15, 1996.

Robert W.L. Veldman is supplying his services to the Company through a
management contract with Beheer-en Beleggingsmaatschapp B.V. ("Management
Company"). His contract specifies that he will be the managing director of
EuroMed Europe and its subsidiaries. Mr. Veldman is considered an employee of
the Management Company and not of EuroMed. Mr. Veldman's compensation shall be
200,000 Dutch Gilders per year (approximately $100,000) for all work done for
the Company. He is also reimbursed 3,000 Dutch Guilders (approximately $1,580)
per month for expenses incurred on behalf of the Company. EuroMed Europe is to
pay these amounts in 12 monthly payments upon invoicing by the Management
Company over the term of this agreement. The term of the Management Company's
agreement is one year from January 1, 1997 to December 31, 1997 and may be
extended upon agreement of both parties. The Management Agreement shall
terminate if (i) EuroMed Europe files bankruptcy; (ii) a suspension of payment
to the Management Company occurs; (iii) Mr. Veldman dies; or (iv) Mr. Veldman is
ill or unable to work for 90 consecutive days. The Management Company
indemnifies EuroMed Europe against any damages caused by the Mr. Veldman's
willful misconduct.

REPORT OF THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS ON EXECUTIVE
COMPENSATION

The Company's executive compensation program is administered by the
Compensation Committee of the Board of Directors. The Compensation Committee
presently consists of one member, Mr. Shuey, who is an independent, nonemployee
director. The Compensation Committee is committed to a strong, positive link
between business, performance and strategic goals, and compensation and benefit
programs.

OVERALL EXECUTIVE COMPENSATION POLICY

The Company's compensation policy is designed to support the overall
objective of enhancing value for the Company's stockholders by:

- Attracting, developing, rewarding and retaining highly qualified and
productive individuals.

- Relating compensation to both Company and individual performance.

- Ensuring compensation levels that are externally competitive and
internally equitable.

- Encouraging executive stock ownership to enhance a mutuality of interest
with other stockholders.

The following is a description of the elements of the Company's executive
compensation and how each relates to the objectives and policy outlined above.

PRE 14A 13th Page of 16 TOC 1st Previous Next ↓Bottom Just 13th

Base Salary

The Committee reviews each executive officer's salary annually. In
determining appropriate salary levels, the Committee considers individual
performance, internal equity, as well as pay practices of other companies
relating to executives of similar responsibility.

By design, the Committee strives to set executives' salaries at competitive
market levels. The Committee believes maximum performance can be encouraged
through the use of appropriate incentive programs. The Company's longterm
compensation philosophy is that long-term incentives should be related to
improvement in long-term stockholder value, thereby creating a mutuality of
interest with stockholders. In furtherance of this objective, the Company
intends to award to its executive officers stock options. Stock options
encourage and reward effective management that results in long-term corporate
financial success, as measured by stock price appreciation.

RATIONALE FOR CEO COMPENSATION

Mr. Hinnen served as Chief Executive Officer of the Company from November
18, 1995 to October 31, 1996. His compensation package was designed to encourage
short and long-term performance in line with the interests of the Company's
stockholders. Mr. Hinnen's large stock ownership percentage as described
elsewhere herein was a substantial incentive to perform in such a way to enhance
stockholders' interest and returns. His base pay was $125,000 for 1995 and
$125,000 for 1996. The Committee believes Mr. Hinnen's total compensation was
competitive in the external marketplace and reflective of Company and individual
performance. The factors which the Committee considered in determining Mr.
Hinnen's base salary for 1996 were those mentioned above for other executive
officers. Mr. Hinnen was not paid an incentive or granted any options under the
Company's 1995 Long-Term Incentive Plan.

Mr. Robert Jansonius, a former director of the Company, and Mr. Shuey
served as temporary Co-Chief Executive Officers of the Company from October 31,
1996 to, in the case of Mr. Jansonius, December 5, 1996, and in the case of Mr.
Shuey, February 28, 1997. Messrs. Shuey and Jansonius were not compensated for
serving in such capacities, but were reimbursed for certain expenses incurred in
connection therewith.

The Compensation Committee Report on Executive Compensation shall not be
deemed incorporated by reference by any general statement incorporating by
reference this proxy statement into any filing under the Securities Act of 1933,
as amended or the Securities Exchange Act of 1934, as amended (the "Exchange
Act"), except to the extent that the Company specifically incorporates this
information by reference, and shall not otherwise be deemed filed under such
Acts.

This report is submitted by the sole member of the Compensation Committee
as of the end of the 1996 fiscal year.

Robert A. Shuey, III

PRE 14A 14th Page of 16 TOC 1st Previous Next ↓Bottom Just 14th

STOCK PERFORMANCE CHART

The following chart compares the yearly percentage change in the cumulative
total stockholder return on the Company's Common Stock from December 23, 1996
through December 31, 1996, with the cumulative total return on the indices. The
comparison assumes $100 was invested immediately prior to such period in Common
Stock and in each of the foregoing indices and assumes reinvestment of
dividends. The Company's classification category is SIC number 512. Dates on the
following chart represent the last day of the indicated fiscal year. The Company
paid no dividends during such period.

COMPARISON OF CUMULATIVE TOTAL RETURN
OF COMPANY, INDUSTRY INDEX AND BROAD MARKET

[Download Table]

MEASUREMENT PERIOD EUROMED, INC.
(FISCAL YEAR COVERED) . INDUSTRY INDEX BROAD MARKET

12/23/96 100.00 100.00 100.00
12/31/96 100.00 103.18 098.02

CERTAIN BUSINESS RELATIONSHIPS

Confedera has had a business relationship with International Procurement
Agency B.V. ("IPA"), a Netherlands based development agency procurer for the
export of pharmaceutical, since July 1994 and entered into a Cooperation
Agreement with IPA on July 10, 1995. Under the Cooperation Agreement, IPA is
primarily responsible for the financial, administrative and logistical
activities concerning the sale of pharmaceutical products and medical consumer
goods and Confedera is responsible for purchasing the pharmaceutical products
and medical consumer goods, quality control and the legal documentation
pertaining thereto. The Cooperation Agreement further provides that (i) the
parties will equally split the profits and losses of their activities, except
that Confedera will receive 66% of the profits (and assume the same percentage
of the losses) for customers located by Confedera, and (ii) as long as
Confedera's prices for goods are competitive, IPA will purchase pharmaceutical
and medical consumer goods exclusively from Confedera, although Confedera shall
be entitled to sell the pharmaceutical and medical consumer goods on a
non-exclusive basis. Mr. Hinnen owns approximately 33% of the capital stock of
Gentrade B.V., which owns 100% of the capital stock of IPA. Mr. Hinnen had
contracted with Gentrade B.V. to acquire an additional 32% of the capital stock
of the Company on or before June 1, 1996, under certain conditions. These
conditions were not met at that time, therefore, Mr. Hinnen did not acquire this
percentage. Further, Mr. Hinnen has a continuing option to purchase another 35%
of Gentrade B.V. if offered by the owner of this stock. The Company believes
that all transactions between IPA and Confedera have been, and will be, on an
arms-length basis.

PRE 14A 15th Page of 16 TOC 1st Previous Next ↓Bottom Just 15th

Mr. Hinnen is the sole owner of the Rhedense Apotheek, a pharmacy located
in Rheden, The Netherlands. In 1994, 1995 and 1996, Rhedense Apotheek purchased
an aggregate of $1,096,000, $1,492,000 and $1,365,941, respectively, of
pharmaceutical from Galenica. The Company believes that all transactions between
Rhedense Apotheek and Galenica have been, and will be, on an arms-length basis.

Mr. Hinnen's wife is the sole owner of Ariano Voorthuizen Beheer B.V.
("AVP"). On September 1, 1993, Galenica borrowed approximately $219,000 from AVP
("AVP Loan"). Interest on the AVP Loan was equal to the promissory note interest
rate of Nederlandsche Bank N.V., plus 2%. The remaining principal balance of,
and accrued but unpaid interest on, the AVP Loan was paid in full by Galenica in
July 1995.

Pursuant to a loan agreement, dated February 1, 1995 ("Hybrida Agreement"),
between Confedera and Hybrida B.V., a Netherlands limited liability company of
which Mr. Hinnen owns 50% of the capital stock ("Hybrida"), Confedera borrowed
approximately $498,000 from Hybrida. The Hybrida Agreement provides for no
interest until January 1, 1999, after which the interest rate shall equal the
promissory note interest rate of Nederlandsche Bank N.V., plus 2%; but in no
event less than 6%. The loan from Hybrida to Confedera is redeemable when the
capital ratio of Confedera is more than 30% and on demand upon the occurrence of
certain events, but such obligation is subordinated to Bank MeesPierson.

Pursuant to a loan agreement dated February 1, 1995 between Galenica and
Wisteria ("Wisteria Agreement"), of which Mr. Hinnen is the sole equity owner,
Galenica borrowed approximately $421,000 from Wisteria. As of December 31, 1996,
the principal balance of this loan had been paid in full.

Since 1991, Pantapharma and Confedera have loaned or advanced money to each
other on a "when needed", and "if available" basis. As of December 31, 1995,
Confedera owed Pantapharma approximately $10,000 which has been since paid in
full. Following the pay-off of the outstanding loan balance, Pantapharma and
Confedera agreed to immediately discontinue such loan arrangement. As a
condition to an amendment to the loan agreement between Confedera, Galenica and
Bank MeesPierson, N.V. on November 9, 1995, Pantapharma agreed to loan to
Confedera approximately $125,000.

It is the policy of the Company that any future transactions with
affiliated individuals or entities will be on terms no less favorable to the
Company than are reasonably available from unrelated third parties, and any such
affiliated transactions will require the approval of a majority of the
independent directors.

SECTION 16 REQUIREMENTS

Section 16(a) of the Exchange Act, requires the Company's officers and
directors, and persons who own more than 10% of a registered class of the
Company's equity securities, to file initial reports of ownership and reports of
changes in ownership with the Securities and Exchange Commission (the "SEC").
Such persons are required by SEC regulation to furnish the Company with copies
of all Section 16(a) forms they file.

Based solely on its review of the copies of such forms received by it with
respect to fiscal 1996, or written representations from certain reporting
persons, the Company believes that all filing requirements applicable to its
officers, directors and persons who own more than 10% of a registered class of
the Company's equity securities have been complied with, except that one Form 5
was filed to report two late Form 4 transactions for Mr. Hinnen, the late Form 3
filing for Wisteria, the direct owner of shares held indirectly by Pantapharma,
which is owned by Mr. Hinnen, and eight late Form 4 transactions for Wisteria
and Pantapharma. Additionally, Louis van den Reek failed to file a Form 3.

PRE 14A Last Page of 16 TOC 1st Previous Next ↓Bottom Just 16th

STOCKHOLDER PROPOSALS

Stockholders may submit proposals on matters appropriate for stockholder
action at subsequent annual meetings of the Company consistent with Rule 14a-8
promulgated under the Exchange Act. For such proposals to be considered in the
Proxy Statement and Proxy relating to the 1998 Annual Meeting of Stockholders,
such proposals must be received by the Company, Attention: Secretary, at the
address set forth on the first page of this Proxy Statement, no later than [NOT
LESS THAN 120 CALENDAR DAYS IN ADVANCE OF DATE OF THE COMPANY'S PROXY STATEMENT
RELEASED IN CONNECTION WITH THE PREVIOUS YEAR'S ANNUAL MEETING], in order to be
included in the Company's proxy materials and form of proxy relating to that
meeting. Stockholder proposals must also be otherwise eligible for inclusion.

OTHER BUSINESS

The Company does not intend to bring any business before the Meeting other
than that described herein and at this date the Company has not been informed of
any matters that may be presented at the Meeting by others; however, if any
other matters properly come before the Meeting or any adjournment thereof, it is
intended that the persons named in the accompanying Proxy will vote pursuant to
such Proxy in accordance with their best judgment on such matters.

MISCELLANEOUS

All costs of solicitation of Proxies will be borne by the Company. In
addition to solicitation by mail, the officers and employees of the Company may
solicit Proxies by telephone or personally, without additional compensation. The
Company may also make arrangements with brokerage houses and other custodians,
nominees and fiduciaries for the forwarding of solicitation materials to the
beneficial owners of shares of Common Stock held of record by such persons, and
the Company may reimburse them for their out-of-pocket expenses incurred in
connection therewith. The Company has engaged American Stock Transfer & Trust
Co. as proxy solicitor for approximately $1,500.

The Annual Report to Stockholders of the Company, including financial
statements for the fiscal year ended December 31, 1996 accompanies this Proxy
Statement. The Annual Report is not to be deemed part of this Proxy Statement.

A COPY OF THE COMPANY'S ANNUAL REPORT ON FORM 10-K, INCLUDING THE FINANCIAL
STATEMENTS AND THE FINANCIAL STATEMENT SCHEDULES, BUT NOT INCLUDING EXHIBITS,
WILL BE FURNISHED AT NO CHARGE TO EACH PERSON TO WHOM A PROXY STATEMENT IS
DELIVERED UPON THE WRITTEN REQUEST OF SUCH PERSON ADDRESSED TO EUROMED, INC.,
ATTN: ROBERT W.L. VELDMAN, WILHELMENAKANAAL NOORD 6, NL 4902VR OOSTERHOUT, THE
NETHERLANDS.

By Order of the Board of Directors,

Richard F. Dahlson
Secretary

Dallas, Texas
April 30, 1997

PRE 14A	1st Page of 16	TOC	↑Top	Previous	Next	↓Bottom	Just 1st

PRE 14A	2nd Page of 16	TOC	1st	Previous	Next	↓Bottom	Just 2nd

PRE 14A	3rd Page of 16	TOC	1st	Previous	Next	↓Bottom	Just 3rd

PRE 14A	4th Page of 16	TOC	1st	Previous	Next	↓Bottom	Just 4th

PRE 14A	5th Page of 16	TOC	1st	Previous	Next	↓Bottom	Just 5th

PRE 14A	6th Page of 16	TOC	1st	Previous	Next	↓Bottom	Just 6th

PRE 14A	7th Page of 16	TOC	1st	Previous	Next	↓Bottom	Just 7th

PRE 14A	8th Page of 16	TOC	1st	Previous	Next	↓Bottom	Just 8th

PRE 14A	9th Page of 16	TOC	1st	Previous	Next	↓Bottom	Just 9th

PRE 14A	10th Page of 16	TOC	1st	Previous	Next	↓Bottom	Just 10th

PRE 14A	11th Page of 16	TOC	1st	Previous	Next	↓Bottom	Just 11th

PRE 14A	12th Page of 16	TOC	1st	Previous	Next	↓Bottom	Just 12th

PRE 14A	13th Page of 16	TOC	1st	Previous	Next	↓Bottom	Just 13th

PRE 14A	14th Page of 16	TOC	1st	Previous	Next	↓Bottom	Just 14th

PRE 14A	15th Page of 16	TOC	1st	Previous	Next	↓Bottom	Just 15th

PRE 14A	Last Page of 16	TOC	1st	Previous	Next	↓Bottom	Just 16th

Dates Referenced Herein and Documents Incorporated by Reference

		Referenced-On Page
This ‘PRE 14A’ Filing	Date	First	Last	Other Filings

	12/31/99	11	12	10-K, 10KSB, NTN 10Q
	1/1/99	15		3
	12/31/97	3	12	10-K
	6/30/97	10		10-Q, 10-Q/A
	6/2/97	7
	5/27/97	7
For Period End:	5/26/97	2	4	DEF 14A
	5/1/97	4
	4/30/97	2	16
Filed on:	4/18/97	3	7	10-K/A
	4/16/97	5	10	10-K/A
	4/3/97	7
	3/26/97	7
	2/28/97	5	13
	2/20/97	9		8-K
	2/18/97	10
	1/1/97	12
	12/31/96	2	16	10-K, 10-K/A, NT 10-K
	12/23/96	14
	12/5/96	13
	11/27/96	6
	11/19/96	9		8-K, 8-K/A
	11/15/96	10
	10/31/96	5	13
	6/1/96	14		3
	2/15/96	12
	12/31/95	15
	11/18/95	5	13
	11/9/95	15
	7/10/95	14
	2/1/95	15
	1/1/95	11	12
	9/1/93	15
				List all Filings

↑Top

Filing Submission 0000950134-97-003038 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Institutional Equity Holdings Inc/NV – ‘PRE 14A’ for 5/26/97

As of: Friday, 4/18/97 · For: 5/26/97 · Accession #: 950134-97-3038 · File #: 0-27720

Preliminary Proxy Solicitation Material — Schedule 14AFiling Table of Contents

Document Table of Contents

Dates Referenced Herein and Documents Incorporated by Reference

Preliminary Proxy Solicitation Material — Schedule 14A
Filing Table of Contents